Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis CEO Calls Potential Schering-Plough Merger “Very Interesting”

This article was originally published in The Tan Sheet

Executive Summary

A Novartis/Schering-Plough merger would increase Novartis' OTC portfolio by about 57% to $2.77 bil. and give the Swiss firm control over the formidable Claritin allergy and hives relief franchise
Advertisement

Related Content

Sanofi-Aventis Combo Leaves Allegra In Rx Territory For Now
Sanofi-Aventis Combo Leaves Allegra In Rx Territory For Now
Sanofi-Aventis Combo Leaves Allegra In Rx Territory For Now
Novartis/Aventis Merger Would Pair Rx-to-OTC Experience With Allegra
Novartis/Aventis Merger Would Pair Rx-to-OTC Experience With Allegra
Novartis/Aventis Merger Would Pair Rx-to-OTC Experience With Allegra
Wyeth Sees Alavert Sales Decline In Fourth Quarter Despite Good Year
Wyeth Sees Alavert Sales Decline In Fourth Quarter Despite Good Year
Triaminic Allerchews
Bristol Sells Its Mead Johnson Adult Nutritionals Business To Novartis

Topics

Advertisement
UsernamePublicRestriction

Register

PS096406

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel